Current News

Contact | Print version | PDF version | Send article | RSS feed

A-Bio Announces Process Development and Clinical Supply Service Agreement with GlaxoSmithKline Biologicals
Agreement with a World Vaccine Leader Marks Major Milestone for Singapore Biologics Contract Manufacturer

04 Nov 2004 - Singapore. A-Bio Pharma Pte Ltd (A-Bio) announced that the company has entered into a process development and clinical supply service agreement with GlaxoSmithKline's vaccine division, GlaxoSmithKline Biologicals (GSK Bio) via the signing of an agreement with Glaxo Wellcome Manufacturing PTE Ltd. This collaboration with a global vaccine player is A-Bio's first commercial agreement since it started operations in November 2003. Under the contract, A-Bio will work closely with GSK Bio to develop and produce clinical lots for one of its many promising vaccine products at A-Bio's GMP facility in Singapore. The companies intend to extend this collaboration to include several other projects in the near future.
 
"We are very pleased to be selected by GSK Bio, one of the world's leading vaccine manufacturers, for the development and production of clinical lots of one of their key potential vaccines," said Dr George Wang, Senior Director of Technical Operations, A-Bio. "Securing this agreement is a significant endorsement of A-Bio's technical competency and ability to cater to the needs of the global market."
 
A-Bio Pharma Pte Ltd is Asia's leading biologics contract manufacturer who provides a full range of manufacturing solutions for mammalian cell culture systems, including process development, optimisation, manufacturing scale-up, GMP production, quality control and regulatory compliance.